Skip to main content
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMPH ISIN · US03209R1032 LEI · 54930055TH0ZLSAQMJ38 US Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2016-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US AMPH

About Amphastar Pharmaceuticals, Inc.

https://amphastar.com/

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging medications. Its portfolio includes generic and proprietary injectable, intranasal, and inhalation products. The company specializes in complex medications such as biologics derived from living cells, proteins, and interchangeable biosimilars. Amphastar also develops innovative drug delivery systems and proprietary technological platforms for various routes of administration.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2016
2016-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the report includes a press release announcing financial results for the three months ended September 30, 2016. The document is only 3002 characters long and primarily serves to furnish the press release as an exhibit. It does not contain the full financial statements or detailed analysis itself, but rather announces the earnings release. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The document is not the full quarterly report (IR) but an announcement of results. Therefore, the correct classification is Earnings Release (ER) with high confidence.
2016-11-08 English
4
Director's Dealing
2016-11-04 English
Regulatory Filings 2016
Regulatory Filings
2016-11-03 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Amphastar Pharmaceuticals to the SEC's Division of Corporation Finance regarding comments on their previously filed SEC reports, specifically the Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and Quarterly Reports on Form 10-Q. The letter addresses specific accounting and disclosure issues raised by the SEC staff, including segment reporting and commitments under supply agreements. The document references the 10-K and 10-Q filings and discusses their content in detail, but it is itself a correspondence letter responding to regulatory comments rather than the actual financial reports. The length is substantial (15,000 characters), and it contains detailed explanations and clarifications, but it is not the report itself. According to the classification rules, such correspondence responding to SEC comment letters is best classified as a Regulatory Filing (RNS), as it does not constitute the original Annual Report or Quarterly Report but is a regulatory communication related to those filings.
2016-10-15 English
4
Director's Dealing
2016-10-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.